ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.

Patients with suspected new bladder cancer were randomly assigned 1:1 to transurethral resection of bladder tumor or ...

The BAMs have a hydrophobic inner surface to prolong microbubble retention within biofluids and a hydrophilic outer layer ...

A cancer-causing chemical is spewing into the air, in Niagara Falls, from the nearby Goodyear plant. That chemical is being ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

Goodyear Tire and Rubber, in Niagara Falls, is being fined $15,000 by the New York State Department of Environmental ...

Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...